NeoGenomics, Inc.
NEONASDAQHealthcare● Active
$10.95
+$0.05(+0.46%)
Market Cap$285163798
P/E Ratio—
52W High$13.74
52W Low$4.72
NeoGenomics, Inc. (NEO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NEO · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.73B | $0.66B | $0.59B | $0.51B | $0.48B |
| Cost of Revenue | $0.44B | $0.37B | $0.35B | $0.32B | $0.30B |
| Gross Profit | $0.28B | $0.29B | $0.24B | $0.19B | $0.19B |
| Gross Margin %(computed) | 38.85% | 43.92% | 41.34% | 36.86% | 38.62% |
| Operating Expenses | |||||
| R&D Expenses | $0.04B | $0.03B | $0.03B | $0.03B | $0.02B |
| G&A Expenses | $0.27B | $0.23B | $0.21B | $0.21B | $0.22B |
| Total Operating Expenses | $0.35B | $0.38B | $0.35B | $0.35B | $0.31B |
| Operating Income | ($0.07B) | ($0.09B) | ($0.11B) | ($0.16B) | ($0.12B) |
| Operating Margin %(computed) | -9.09% | -13.94% | -18.21% | -30.92% | -24.52% |
| Interest Income | $0.01B | $0.02B | $0.02B | $0.01B | $0.00B |
| Interest Expense | $0.00B | $0.01B | $0.01B | $0.01B | $0.01B |
| Income Before Tax | ($0.11B) | ($0.08B) | ($0.10B) | ($0.16B) | ($0.02B) |
| Income Tax Expense | ($0.00B) | ($0.00B) | ($0.01B) | ($0.02B) | ($0.01B) |
| Net Income | ($0.11B) | ($0.08B) | ($0.09B) | ($0.14B) | ($0.01B) |
| Net Margin %(computed) | -14.85% | -11.92% | -14.87% | -28.30% | -1.72% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-4.20 | $-3.10 | $-3.50 | $-5.80 | $-0.35 |
| Wtd Avg Shares | 0.03B | 0.03B | 0.03B | 0.02B | 0.02B |
| EBITDA | $0.00B | ($0.00B) | ($0.02B) | ($0.08B) | ($0.07B) |
| EBITDA Margin %(computed) | 0.24% | -0.23% | -2.98% | -16.15% | -13.50% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more NeoGenomics, Inc. data
About NeoGenomics, Inc. (NEO) Income Statement
NeoGenomics, Inc. (NEO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, NEO reported revenue of $0.73B, gross profit of $0.28B (gross margin 38.85%), and net income of ($0.11B) — a net profit margin of -14.85%.
Frequently asked questions
NEO · 4 questionsNeoGenomics, Inc. (NEO) reported revenue of $0.73B for 2025, up 10.1% year-over-year.
NEO revenueNEO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09